Company profile
International Stem Cell Corporation
OTC: ISCO · Healthcare · Biotechnology
#642 of 1,418 Healthcare companies by revenue42nd-percentile growth
EA Score
57CFH 52DQ 65GM 58SS 53
v0.1 · 65/100 weight · provisional
↑ disclosure history, growth stability · ↓ return on equity, Altman-Z
Methodology →Revenue TTM
$9.3M
Rev growth YoY (TTM)
+2.2%
Net income (FY)
-$418.0k
Employees
33
as of 2026-08-25
Market cap
$4.0M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$9.1M$9.1M2025
Net income-$418.0k-$418.0k2025
Operating income-$267.0k-$267.0k2025
Total assets$4.8M$4.8M2025
Liabilities$4.6M$4.6M2025
Equity-$4.1M-$4.1M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Biomedical Market93%
Anti Aging Market7%
By geography
Asia57%
Europe35%
Other Regions8%
The read
What is International Stem Cell Corporation’s revenue?
International Stem Cell Corporation booked $9.1M in FY2025 revenue, growing 0.2% year over year — about the middle of the pack among Healthcare companies we track, at a -4.6% net margin.
Peers · Healthcare
ThermoGenesis Holdings, Inc.——Curis, Inc.53DRafarma Pharmaceuticals, Inc.71BNeuroOne Medical Technologies Corporation55CHempfusion Wellness Inc.——CareView Communications, Inc.52DNeighbors
San Diego →Key facts
CEOAndrey Semechkin
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeOTC: ISCO
Employees33
IPO date2007-05-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.